108 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
21 Recruiting PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions: Drug: FOLFOX regimen;   Drug: carboplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: paclitaxel
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 204
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01333033
22 Recruiting Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design:
Number Enrolled:
Gender: Both
Age Groups: Child / Adult / Senior
NCT Number: NCT00897767
23 Recruiting Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Conditions: Prostate Cancer;   Sexual Dysfunction and Infertility;   Sexuality
Interventions: Other: communication intervention;   Other: counseling intervention;   Other: nutrition intervention;   Other: questionnaire administration
Study Type: Interventional
Phase:
Funder Type: Other
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Primary Purpose: Supportive Care;   Masking: Open Label
Number Enrolled: 372
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01982058
24 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: riluzole;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 36
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01303341
25 Recruiting Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Estrogen Receptor-negative Breast Cancer;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HER2-negative Breast Cancer;   Intraocular Lymphoma;   Male Breast Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progesterone Receptor-negative Breast Cancer;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Breast Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Breast Cancer;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Breast Cancer;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: veliparib;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 80
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00740805
26 Not yet recruiting Internet-Based Weight-Loss Program for Colorectal Cancer Survivors
Conditions: Cancer Survivor;   Colorectal Cancer;   Weight Changes
Intervention: Behavioral: Internet weight loss intervention
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Health Services Research;   Masking: Open Label
Number Enrolled: 60
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01032590
27 Recruiting Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Condition: Bladder Cancer
Interventions: Biological: TICE Bacillus Calmette-Guerin (BCG);   Biological: PANVAC
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH / Other
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 54
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02015104
28 Recruiting 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate;   Drug: Abiraterone acetate plus degarelix;   Drug: Degarelix
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 120
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT01751451
29 Recruiting Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
Condition: Acute Myeloid Leukemia
Interventions: Drug: Phase I- Cytarabine & Eltrombopag;   Drug: Phase II- Sequence A;   Drug: Phase II- Sequence B
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: Other / Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject, Caregiver, Investigator)
Number Enrolled: 90
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01656252
30 Recruiting Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: gemcitabine
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: Other
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 25
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01893801
31 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 4000
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT01272037
32 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: quality-of-life assessment
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1500
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01274338
33 Recruiting Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Condition: Ductal Breast Carcinoma in Situ
Interventions: Biological: trastuzumab;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 2000
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT00769379
34 Recruiting Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Large Cell Lung Cancer;   Metastatic Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: veliparib;   Other: placebo;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 168
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01642251
35 Recruiting Psychological Interventions for Gynecologic Cancer
Condition: Gynecologic Cancer
Intervention: Behavioral: Psychotherapy
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Primary Purpose: Supportive Care;   Masking: Open Label
Number Enrolled: 401
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT01951807
36 Recruiting Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Conditions: Brain Tumor;   Central Nervous System Tumor
Interventions: Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 510
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT00085735
37 Recruiting Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design:
Number Enrolled: 1272
Gender: Both
Age Groups: Child / Adult / Senior
NCT Number: NCT00900250
38 Recruiting Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design:
Number Enrolled:
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT00919750
39 Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure;   Other: informational intervention
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design:
Number Enrolled:
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT01000753
40 Recruiting Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design:
Number Enrolled:
Gender: Both
Age Groups: Child / Adult
NCT Number: NCT00897325

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years